OK Biotech Co., Ltd. (4155.TW)
TWD 20.9
(-0.71%)
TWD 20.9
(-0.71%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 196.88 Million TWD | -40.77% |
| 2022 | 344.95 Million TWD | 84.64% |
| 2021 | 186.82 Million TWD | -42.68% |
| 2020 | 325.95 Million TWD | 10.07% |
| 2019 | 296.12 Million TWD | -1.98% |
| 2018 | 302.1 Million TWD | 4.88% |
| 2017 | 288.05 Million TWD | 36.79% |
| 2016 | 210.57 Million TWD | -23.95% |
| 2015 | 276.89 Million TWD | 66.37% |
| 2014 | 166.43 Million TWD | -42.79% |
| 2013 | 290.92 Million TWD | 50.21% |
| 2012 | 193.68 Million TWD | 43.45% |
| 2011 | 135.01 Million TWD | 39.53% |
| 2010 | 96.76 Million TWD | -0.98% |
| 2009 | 97.72 Million TWD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 43.41 Million TWD | 67.87% |
| 2024 Q2 | 96.86 Million TWD | 123.13% |
| 2023 Q4 | 25.86 Million TWD | -23.59% |
| 2023 FY | 204.31 Million TWD | -40.77% |
| 2023 Q1 | 74.94 Million TWD | 5.18% |
| 2023 Q3 | 33.84 Million TWD | -49.95% |
| 2023 Q2 | 67.62 Million TWD | -9.78% |
| 2022 Q3 | 68.9 Million TWD | -40.18% |
| 2022 Q1 | 89.62 Million TWD | 74.09% |
| 2022 FY | 344.95 Million TWD | 84.64% |
| 2022 Q4 | 71.25 Million TWD | 3.41% |
| 2022 Q2 | 115.17 Million TWD | 28.51% |
| 2021 Q1 | 48.74 Million TWD | -51.3% |
| 2021 FY | 186.82 Million TWD | -42.68% |
| 2021 Q4 | 51.48 Million TWD | 20.13% |
| 2021 Q3 | 42.85 Million TWD | -2.03% |
| 2021 Q2 | 43.74 Million TWD | -10.25% |
| 2020 Q4 | 100.08 Million TWD | 38.4% |
| 2020 Q2 | 53.21 Million TWD | -46.98% |
| 2020 FY | 325.95 Million TWD | 10.07% |
| 2020 Q1 | 100.35 Million TWD | 29.92% |
| 2020 Q3 | 72.31 Million TWD | 35.9% |
| 2019 Q1 | 69.32 Million TWD | -28.59% |
| 2019 Q3 | 74.96 Million TWD | 0.48% |
| 2019 Q2 | 74.6 Million TWD | 7.62% |
| 2019 Q4 | 77.24 Million TWD | 3.04% |
| 2019 FY | 296.12 Million TWD | -1.98% |
| 2018 Q2 | 48.66 Million TWD | -32.96% |
| 2018 Q3 | 83.77 Million TWD | 72.13% |
| 2018 Q4 | 97.07 Million TWD | 15.88% |
| 2018 FY | 302.1 Million TWD | 4.88% |
| 2018 Q1 | 72.59 Million TWD | 6.76% |
| 2017 Q3 | 85.97 Million TWD | 25.09% |
| 2017 Q4 | 67.99 Million TWD | -20.91% |
| 2017 FY | 288.05 Million TWD | 36.79% |
| 2017 Q1 | 65.34 Million TWD | 206.6% |
| 2017 Q2 | 68.73 Million TWD | 5.18% |
| 2016 FY | 210.57 Million TWD | -23.95% |
| 2016 Q3 | 45.99 Million TWD | -31.88% |
| 2016 Q4 | 21.31 Million TWD | -53.66% |
| 2016 Q2 | 67.51 Million TWD | -10.88% |
| 2016 Q1 | 75.75 Million TWD | 3.62% |
| 2015 FY | 276.89 Million TWD | 66.37% |
| 2015 Q4 | 73.11 Million TWD | 0.0% |
| 2015 Q3 | 73.11 Million TWD | 11.9% |
| 2015 Q2 | 65.33 Million TWD | 0.0% |
| 2015 Q1 | 65.33 Million TWD | 101.5% |
| 2014 Q1 | 50.79 Million TWD | -29.74% |
| 2014 Q2 | 50.79 Million TWD | 0.0% |
| 2014 Q4 | 32.42 Million TWD | 0.0% |
| 2014 Q3 | 32.42 Million TWD | -36.16% |
| 2014 FY | 166.43 Million TWD | -42.79% |
| 2013 Q2 | 73.17 Million TWD | 0.0% |
| 2013 Q1 | 73.17 Million TWD | 46.93% |
| 2013 Q3 | 72.29 Million TWD | -1.2% |
| 2013 Q4 | 72.29 Million TWD | 0.0% |
| 2013 FY | 290.92 Million TWD | 50.21% |
| 2012 FY | 193.68 Million TWD | 43.45% |
| 2012 Q3 | 49.79 Million TWD | 0.0% |
| 2012 Q4 | 49.79 Million TWD | 0.0% |
| 2012 Q2 | - TWD | 0.0% |
| 2011 FY | 135.01 Million TWD | 39.53% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 Q4 | - TWD | 0.0% |
| 2010 FY | 96.76 Million TWD | -0.98% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | 97.72 Million TWD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 1.62 Billion TWD | 87.862% |
| Apex Medical Corp. | 1.13 Billion TWD | 82.704% |
| Applied BioCode Corporation | 268.73 Million TWD | 26.738% |